Recognizing and Diagnosing Acquired Hemophilia | NovoSeven® RT (Coagulation Factor VIIa [Recombinant])

Recognizing and Diagnosing Acquired Hemophilia (7:46)

Acquired hemophilia is extremely rare and can be difficult to diagnose. Learn to spot the signs of this serious condition.

Please click here for Prescribing Information.

0215-00025272-1

Play

Pause

Skip

Volume

Chapters

Transcript

References

Subtitles

Fullscreen

Chapters

Transcript

References

Acquired hemophilia is extremely rare and can be difficult to diagnose. Learn to spot the signs of this serious condition.

WARNING: THROMBOSIS

Serious arterial and venous thrombotic events following administration of NovoSeven^®RT have been reported.
Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven^® RT.
Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

NovoSeven^® RT (Coagulation Factor VIIa [Recombinant]) is a coagulation factor indicated for:

Treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
Treatment of bleeding episodes and peri-operative management in adults with acquired hemophilia

WARNING: THROMBOSIS

Serious arterial and venous thrombotic events following administration of NovoSeven^® RT have been reported.
Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven^® RT.
Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

Warnings and Precautions

Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.
Exercise caution when administering NovoSeven^® RT to patients with an increased risk of thromboembolic complications, such as those with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, uncontrolled post-partum hemorrhage, history of coronary heart disease, liver disease, post-operative immobilization, in elderly patients, in neonates, or in patients receiving concomitant treatment with aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates).
Hypersensitivity reactions, including anaphylaxis, have been reported with NovoSeven^® RT. Administer only if clearly needed in patients with known hypersensitivity to NovoSeven^® RT, any of its components, or mouse, hamster, or bovine proteins. Should symptoms occur, discontinue NovoSeven^® RT and administer appropriate treatment.
Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed.
Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis.

Adverse Reactions

The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven^® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia.

Drug Interactions

Thrombosis may occur if NovoSeven^® RT is administered concomitantly with Coagulation Factor XIII.

Please click here for Prescribing Information.